References
- 1
Allison R C, Bedsole D L.
The other medical causes of rhabdomyolysis.
Am J Med Sci.
2003;
326
79-88
- 2
Bhana N, Foster R H, Olney R, Plosker G L.
Olanzapine: an updated review of its use in the management of schizophrenia.
Drugs.
2001;
61
111-116
- 3
Beasley C M, Tollefson G D, Tran P V.
Safety of olanzapine.
J Clin Psychiatry.
1997;
58 (Suppl 10)
13-17
- 4
Farooque R.
Uncommon side effects associated with olanzapine.
Pharmacopsychiatry.
2003;
36
83
- 5
Johnson V, Bruxner G.
Neuroleptic malignant syndrome associated with olanzapine.
Aust N Z J Psychiatry.
1998;
32
884-886
- 6
Kopf A, Köster J, Schulz A, Krömker H, Becker T.
Life threatening neuroleptic malignant syndrome due to olanzapine.
Psychiatr Prax.
2003;
30
279-282
- 7
Löffler W, Kilian R, Toumi M, Angermeyer M C.
Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic
treatment.
Pharmacopsychiatry.
2003;
36
105-112
- 8
Marcus E L, Vass A, Zislin J.
Marked elevation of serum creatine kinase associated with olanzapine therapy.
Ann Pharmacother.
1999;
33
697-700
- 9
Meltzer H Y.
Skeletal muscle necrosis following membrane-active drugs plus serotonin.
J Neurol Sci.
1976;
28
41-56
- 10
Meltzer H Y, Cola P A, Parsa M.
Marked elevation of serum creatine kinase activity associated with antipsychotic drug
treatment.
Neuropsychopharmacology.
1996;
15
395-405
- 11
Moretti-Rojas I, Ezrailson E G, Birnbaumer L, Entman M L, Garber A J.
Serotonergic and adrenergic regulation of skeletal muscle metabolism in the rat. II.
The use of 125iodolysergic acid diethylamide and 125iodopindolol as probes of sarcolemmal receptor function and specificity.
J Biol Chem.
1983;
258
12 499-12 508
- 12
Poels P JE, Gabreels F JM.
Rhabdomyolysis: a review of the literature.
Clin Neurol Neurosurg.
1993;
95
175-192
- 13
Rosebraugh C J, Flockhart D A, Yasuda S U, Woosley R L.
Olanzapine-induced rhabdomyolysis.
Ann Pharmocother.
2001;
35
1020-1023
- 14
Shuster J.
Olanzapine and rhabdomyolysis.
Nursing.
2000;
30
87
- 15
Stanfield S C, Privette T.
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.
J Emerg Med.
2000;
19
355-357
- 16
Vanholder R, Mehmet S, Ekrem E, Lamiere N.
Rhabdomyolysis.
J Am Soc Nephrol.
2000;
11
1553-1561
- 17 http://www.akdae.de.20/20/Archiv/2002/20 020 315.html
Hermann Spießl, M.D.
Bezirksklinikum Regensburg
93042 Regensburg
Germany
Phone: +49 941 941 1604
Fax: +49 941 941 1605
Email: hermann.spiessl@bkr-regensburg.de
